We have observed
11 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after April 18, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY
POLYSACCHARIDES COMPRISING TWO ANTITHROMBIN III-BINDING SITES, PREPARATION THEREOF AND USE THEREOF AS ANTITHROMBOTIC MEDICAMENTS
SEMULOPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS RECEIVING CHEMOTHERAPY
AN ANTITUMORAL COMBINATION COMPRISING OMBRABULIN, A TAXANE DERIVATIVE AND A PLATINUM DERIVATIVE
SEMULOPARIN FOR USE AS AN ANTITHROMBOTIC TREATMENT IN HIP REPLACEMENT SURGERY WITH IMPROVED SAFETY IN TERMS OF CLINICALLY RELEVANT BLEEDINGS
SEMULOPARIN FOR THE PREVENTION OF A MORTALITY AND/OR MORBIDITY EVENT IN A PATIENT UNDERGOING MAJOR ORTHOPAEDIC SURGERY
SEMULOPARIN FOR THE EXTENDED PREVENTION OF A MORTALITY AND/OR MORBIDITY EVENT IN A PATIENT HAVING UNDERGONE HIP FRACTURE SURGERY
Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
IDRABIOTAPARINUX FOR THE TREATMENT OF PULMONARY EMBOLISM AND FOR THE SECONDARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS
PYRAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF BLADDER CANCER
DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS